Leukemia, Acute Lymphoblastic 3 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ALL3 MCID: LKM060 MIFTS: 43	Leukemia, Acute Lymphoblastic 3 (ALL3) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic 3

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 3:

Name: Leukemia, Acute Lymphoblastic 3 ⁵⁷

Leukemia, Acute Lymphoblastic, Susceptibility to, 3 ⁵⁷ ²⁸ ⁵ ³⁸ ⁷¹

Precursor B-Cell Lymphoblastic Leukemia ⁷¹ ⁷⁵

Precursor B-Cell Acute Lymphoblastic Leukemia/lymphoma ⁵⁸

Precursor B-Cell Acute Lymphocytic Leukemia/lymphoma ⁵⁸

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ⁷¹

Precursor B-Cell Acute Lymphoblastic Leukemia ⁵⁸

Precursor B-Cell Acute Lymphocytic Leukemia ⁵⁸

Burkitt Lymphoma ⁷¹

B-All ⁵⁸

All3 ⁵⁷

Characteristics:

Age Of Onset:

Precursor B-Cell Acute Lymphoblastic Leukemia: Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Acute lymphoblastic leukaemia [ALL]

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

OMIM® ⁵⁷ 615545

ICD10 via Orphanet ³² C91.0

UMLS via Orphanet ⁷² C0006413 C1292769

Orphanet ⁵⁸ ORPHA99860

UMLS ⁷¹ C0006413 C0023485 C1292769 more

Sources

Summaries for Leukemia, Acute Lymphoblastic 3

Orphanet: ⁵⁸ A rare acute lymphoblastic leukemia characterized by infiltration of bone marrow and peripheral blood by small to medium-sized blast cells typically positive for the B-cell markers CD19, cCD79a, and cCD22. Predilection sites for extramedullary involvement are the central nervous system, lymph nodes, spleen, liver, and testes. Patients present with evidence of bone marrow failure (i. e. thrombocytopenia, anemia, and/or neutropenia) and variable leukocyte count, as well as lymphadenopathy, hepatomegaly, splenomegaly, bone pain, and arthralgias.

MalaCards based summary: Leukemia, Acute Lymphoblastic 3, also known as leukemia, acute lymphoblastic, susceptibility to, 3, is related to b-lymphoblastic leukemia/lymphoma and b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), and has symptoms including bone pain An important gene associated with Leukemia, Acute Lymphoblastic 3 is PAX5 (Paired Box 5). The drugs Ifosfamide and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells.

Wikipedia: ⁷⁵ Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell... more...

More information from OMIM: 615545

Sources

Related Diseases for Leukemia, Acute Lymphoblastic 3

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2

Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)

#	Related Disease	Score
1	b-lymphoblastic leukemia/lymphoma	11.6
2	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	11.4
3	leukemia, acute lymphoblastic	11.4
4	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	11.3
5	b-lymphoblastic leukemia/lymphoma with etv6-runx1	11.1
6	b-lymphoblastic leukemia/lymphoma with hypodiploidy	11.1
7	b-lymphoblastic leukemia/lymphoma with bcr-abl1	11.1
8	b-lymphoblastic leukemia/lymphoma mll rearranged	11.1
9	b-lymphoblastic leukemia/lymphoma with hyperdiploidy	11.1
10	b-lymphoblastic leukemia/lymphoma with il3-igh	11.1
11	b-lymphoblastic leukemia/lymphoma with tcf3-pbx1	11.1
12	b-lymphoblastic leukemia/lymphoma with iamp21	11.1
13	glycogen storage disease ii	10.9
14	agammaglobulinemia 8b, autosomal recessive	10.9
15	hemophagocytic lymphohistiocytosis, familial, 1	10.5
16	hemophagocytic lymphohistiocytosis	10.5
17	leukemia	10.5
18	sarcoma	10.4
19	congenital hemidysplasia with ichthyosiform erythroderma and limb defects	10.3
20	children's interstitial lung disease	10.3
21	burkitt lymphoma	10.3
22	acute leukemia	10.3
23	acute erythroid leukemia	10.3
24	erythroleukemia	10.3
25	toxic encephalopathy	10.3
26	hematologic cancer	10.2
27	graft-versus-host disease	10.2
28	lymphoma	10.2
29	childhood acute lymphocytic leukemia	10.2
30	autoimmune disease	10.2
31	leukemia, acute monocytic	10.2
32	isolated growth hormone deficiency, type ii	10.2
33	prostate cancer	10.2
34	fanconi anemia, complementation group d2	10.2
35	lymphoblastic leukemia, acute, with lymphomatous features	10.2
36	myasthenia gravis	10.2
37	myelofibrosis	10.2
38	isolated growth hormone deficiency, type iii, with agammaglobulinemia	10.2
39	leukemia, acute lymphoblastic 2	10.2
40	bainbridge-ropers syndrome	10.2
41	vitamin b12 deficiency	10.2
42	interleukin-7 receptor alpha deficiency	10.2
43	isolated growth hormone deficiency type iii	10.2
44	horner's syndrome	10.2
45	hepatitis a	10.2
46	pure red-cell aplasia	10.2
47	cholestasis	10.2
48	obstructive jaundice	10.2
49	myeloproliferative neoplasm	10.2
50	acute pancreatitis	10.2

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic 3:

Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 3

Clinical features from OMIM®:

615545 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Acute Lymphoblastic 3:

bone pain

Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 3

Drugs for Leukemia, Acute Lymphoblastic 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ifosfamide

Approved

Phase 4

3778-73-2

3690

Vindesine

Approved, Investigational

Phase 4

59917-39-4, 53643-48-4

40839

Lomustine

Approved, Investigational

Phase 4

13010-47-4

3950

Palifosfamide

Investigational

Phase 4

31645-39-3

100427

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6, 202138-50-9

464205 6398764

Anti-Retroviral Agents

Phase 4

Anti-HIV Agents

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Mycophenolic acid

Approved, Investigational

Phase 3

24280-93-1

446541

Tacrolimus

Approved, Investigational

Phase 3

104987-11-3

6473866 445643

Aldesleukin

Approved

Phase 3

110942-02-4

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Vidarabine

Approved, Investigational

Phase 3

24356-66-9

21704

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pegaspargase

Approved, Investigational

Phase 3

130167-69-0

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

Mercaptopurine

Approved

Phase 3

50-44-2

667490

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Cytarabine

Approved, Investigational

Phase 3

147-94-4

6253

Clofarabine

Approved, Investigational

Phase 3

123318-82-1

119182

Blinatumomab

Approved, Investigational

Phase 3

853426-35-4

Dasatinib

Approved, Investigational

Phase 3

302962-49-8

3062316

Ichthammol

Approved

Phase 3

8029-68-3

Tioguanine

Approved

Phase 3

154-42-7

2723601

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Aspartic acid

Approved, Nutraceutical

Phase 3

56-84-8

5960

Asparagine

Approved, Investigational, Nutraceutical

Phase 3

70-47-3

6267

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Cyclosporins

Phase 3

Interleukin-2

Phase 3

Analgesics, Non-Narcotic

Phase 3

Imatinib Mesylate

Phase 3

220127-57-1

Neuroprotective Agents

Phase 3

Methylprednisolone Acetate

Phase 3

584547

Antiemetics

Phase 3

Gastrointestinal Agents

Phase 3

Folic Acid Antagonists

Phase 3

Interventional clinical trials:

(show top 50) (show all 314)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy	Unknown status	NCT02585947	Phase 4	Tenofovir
2	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
3	Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4	B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)	Recruiting	NCT05518383	Phase 4	Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
5	A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE	Active, not recruiting	NCT03677596	Phase 4	inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
6	LMBA02 Protocol for Patients With a Burkitt Lymphoma	Unknown status	NCT00180882	Phase 3	rituximab
7	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
8	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma	Completed	NCT00002649	Phase 3	cyclophosphamide;etoposide
9	A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101)	Completed	NCT01597778	Phase 3
10	Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph	Completed	NCT00327678	Phase 3	Rituximab;Imatinib Mesylate
11	Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial	Recruiting	NCT05020392	Phase 3	BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells;Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
12	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy	Recruiting	NCT03959085	Phase 3	Calaspargase Pegol-mknl;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
13	A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)	Recruiting	NCT03914625	Phase 3	Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine Sulfate
14	Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	Active, not recruiting	NCT02101853	Phase 3	Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
15	Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)	Active, not recruiting	NCT01190930	Phase 3	Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
16	A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations	Active, not recruiting	NCT02883049	Phase 3	Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
17	Phase II Trial of CLAG-M in Relapsed ALL	Unknown status	NCT01513603	Phase 2	CLAG-M
18	Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients	Unknown status	NCT03142646	Phase 1, Phase 2
19	A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)	Completed	NCT00849147	Phase 2
20	A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)	Completed	NCT00864227	Phase 2
21	A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment	Completed	NCT01116193	Phase 2	Lenalidomide plus dexamethasone
22	A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	Completed	NCT01700946	Phase 2	dexamethasone;vincristine sulfate;clofarabine;cyclophosphamide;etoposide;pegaspargase;methotrexate;mercaptopurine;cytarabine;mitoxantrone;teniposide;vinblastine;therapeutic hydrocortisone
23	S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia	Completed	NCT00945815	Phase 2	clofarabine;cytarabine
24	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial	Completed	NCT00105001	Phase 2	Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
25	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
26	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
27	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
28	A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation	Completed	NCT01789255	Phase 2	vorinostat;tacrolimus;cyclosporine;methotrexate
29	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
30	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
31	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
32	A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation	Completed	NCT00064246	Phase 1, Phase 2
33	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
34	Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies	Completed	NCT00867529	Phase 2
35	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
36	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
37	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
38	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
39	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
40	High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma	Completed	NCT01177371	Phase 2	busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
41	A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation	Completed	NCT01427881	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
42	Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia	Completed	NCT00039130	Phase 2	cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;prednisone;vincristine sulfate;Allopurinol
43	Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma	Completed	NCT01516593	Phase 2	Induction Phase;Consolidation Phase (on day +50);Intensification phase;BEAM conditioning
44	A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma	Completed	NCT01842672	Phase 1, Phase 2	Clofarabine;Mitoxantrone
45	A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	NCT00073918	Phase 2	cyclophosphamide;etoposide
46	A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas	Completed	NCT00054639	Phase 2
47	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
48	A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma	Completed	NCT00119392	Phase 2	cyclosporine;fludarabine phosphate;mycophenolate mofetil
49	Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas	Completed	NCT00001237	Phase 2	granulocyte-macrophage colony stimulating factor (GM-CSF)
50	A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas	Completed	NCT00058019	Phase 2	ixabepilone

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 3

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cyclophosphamide

Sources

Genetic Tests for Leukemia, Acute Lymphoblastic 3

Genetic tests related to Leukemia, Acute Lymphoblastic 3:

#	Genetic test	Affiliating Genes
1	Leukemia, Acute Lymphoblastic, Susceptibility to, 3 ²⁸	PAX5

Sources

Anatomical Context for Leukemia, Acute Lymphoblastic 3

Organs/tissues related to Leukemia, Acute Lymphoblastic 3:

MalaCards : Bone Marrow, Bone, T Cells, Liver, Testes, Spleen, Myeloid

Sources

Publications for Leukemia, Acute Lymphoblastic 3

Articles related to Leukemia, Acute Lymphoblastic 3:

(show top 50) (show all 9314)

#	Title	Authors	PMID	Year
1	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. ⁶² ⁵⁷ ⁵	Shah S...Offit K	24013638	2013
2	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. ⁶² ⁵⁷	Gu Z...Mullighan CG	30643249	2019
3	Precursor B-cell acute lymphoblastic leukemia in a pediatric patient with Bainbridge-Ropers syndrome. ⁶²	Slatnick LR...Hartman L	35733401	2023
4	Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. ⁶²	McCall D...Cuglievan B	36031729	2023
5	Performance comparison of systemic activity correction in functional near-infrared spectroscopy for methods with and without short distance channels. ⁶²	Klein F...Kranczioch C	36248616	2023
6	Impact of COVID 19 on erectile function. ⁶²	Adeyemi DH...Akhigbe RE	35924485	2022
7	Neurochemical correlates of cognitive functions in euthymic patients with bipolar disorder: 1H-MRS study. ⁶²	Gupta R...Chadda RK	36270047	2022
8	The Value of Intraoperative Magnetic Resonance Imaging in Endoscopic Endonasal Resection of Pituitary Adenoma. ⁶²	Patel A...Pacione D	36393881	2022
9	Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors. ⁶²	Yang S...Xing D	36196773	2022
10	Performance of cone-beam computed tomography (CBCT) renal arteriography for renal tumor embolization. ⁶²	Kim MS...Cho YS	36399872	2022
11	Justification for initiating patiromer when restricted by prior authorization and clinical guidance in a US health care system. ⁶²	Patel S...Sauer BC	36427342	2022
12	In silico analysis of a novel protein in CAR T- cell therapy for the treatment of hematologic cancer through molecular modelling, docking, and dynamics approach. ⁶²	Mohanty R...Ganguly N	36395593	2022
13	Microwave assisted synthesis of 2-amino-4-chloro-pyrimidine derivatives: Anticancer and computational study on potential inhibitory action against COVID-19. ⁶²	Qureshi F...Bin Break MK	36276298	2022
14	M-Sn-Q (M = Zn, Cd; Q = S, Se) Compounds Templated by (Alkyl)ammonium Species: Synthesis, Crystal Structure, and Sr2+ Adsorption Property. ⁶²	Wang KY...Wang C	36395523	2022
15	Revisiting the Newly Modified Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) and Reporting Newly Identified Genes. ⁶²	Chang E...Shehata BM	34854351	2022
16	Comparison of Ultrashort TE Lung MRI and HRCT Lungs for Detection of Pulmonary Nodules in Oncology Patients. ⁶²	Periaswamy G...Cherian M	36451941	2022
17	Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene Variants. ⁶²	Carlens J...Rayment JH	35767027	2022
18	Women's experiences of a pregnancy whilst attending a specialist antenatal service for pregnancies after stillbirth or neonatal death: a qualitative interview study. ⁶²	Smith DM...Heazell AEP	35853021	2022
19	A Retrospective Review of the Characteristics and Outcomes of Patients through an Integrated Palliative Care Model during the First Wave of the SARS-COV-2 Pandemic. ⁶²	Liu K...Karlekar M	36108157	2022
20	Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. ⁶²	Duan H...Iagaru A	35552245	2022
21	You Hurt Me, so I Hurt Myself and Others: How Does Childhood Emotional Maltreatment Affect Adolescent Violent Behavior and Suicidal Ideation? ⁶²	Wang X...Li W	35130779	2022
22	Human parainfluenza 3 and respiratory syncytial viruses detected in pangolins. ⁶²	Que T...Tong Y	35678141	2022
23	Comparison of Three Approaches to Single-Port Robot-Assisted Radical Prostatectomy: Our Institution's Initial Experience. ⁶²	Balasubramanian S...Kim EH	36017625	2022
24	Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula. ⁶²	Te N...Bensaid A	34918620	2022
25	SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond. ⁶²	Dekker SE...Muffly L	36130863	2022
26	Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report. ⁶²	Karimi H...Gholizadeh M	36471442	2022
27	Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia. ⁶²	Tang B...Zhou H	36056210	2022
28	Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. ⁶²	Yuti P...Sujjitjoon J	36435066	2022
29	Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac? ⁶²	Napolitano S...Balduzzi A	34674588	2022
30	Actinomortierella wolfii: Identity and pathology. ⁶²	Sigera LSM...de Hoog S	36393998	2022
31	Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. ⁶²	Koleilat A...Baughn LB	35771717	2022
32	A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL). ⁶²	Johnson S...Gota V	36251032	2022
33	De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion. ⁶²	Hameed M...Alfayez M	36448578	2022
34	Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. ⁶²	Shi Z...Chen B	35622074	2022
35	Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. ⁶²	Saygin C...Muffly L	36453516	2022
36	Establishment and Verification of a Prediction Model for Identifying Pathologic Infections Based on the Clinical Characteristics of Epidermoid Cysts. ⁶²	Ren H...Gao X	36374320	2022
37	Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome: A Randomized Controlled Trial. ⁶²	Elshafey MA...Alsakhawi RS	35533737	2022
38	Shaking up the silence: consequences of HMGN1 antagonizing PRC2 in the Down syndrome brain. ⁶²	Farley SJ...Zeldich E	36463299	2022
39	The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. ⁶²	Faruqi AJ...Shah NN	35939781	2022
40	Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry. ⁶²	Moreno-Fernandez J...SPAIP Registry Study	35947087	2022
41	Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. ⁶²	Cutini I...Saccardi R	36116729	2022
42	Transoral Endoscopic Thyroidectomy by Vestibular Approach for Papillary Thyroid Carcinoma with Tumor Size ≥2 cm. ⁶²	Chen ZX...Qin Y	36445736	2022
43	Occurrence of familial Mediterranean fever in haemophilia patients. ⁶²	Kirkiz S...Kocak U	36409293	2022
44	Comparison of Cost and Perioperative Outcomes Among Patients Undergoing Simple Prostatectomy and Laser Enucleation of the Prostate. ⁶²	Hawken SR...Friedlander DF	36193580	2022
45	Clinical Observation of Double Percutaneous Nephrostomy Combined with Ureter Occlusion Stent for Treating Cervical Cancer Complicated with Vesicovaginal Fistula. ⁶²	Duan XH...Zhang YC	33016777	2022
46	Prediction of exercise-induced desaturation in COPD patients without resting hypoxemia: a retrospective study. ⁶²	Yang L...Yang T	36348483	2022
47	[Genetics and clinical phenotypes of epilepsy associated with chromosome 2q24.3 microdeletion]. ⁶²	Zhao N...Zhang YH	36319147	2022
48	Evaluation of a Cranial Ultrasound Screening Protocol for Very Preterm Infants. ⁶²	McLean G...Lombardo P	36321412	2022
49	Shear wave elastography to evaluate carotid artery elasticity in long-term drinkers with varying degrees of alcoholic fatty liver disease. ⁶²	Li X...Yu T	36385468	2022
50	Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. ⁶²	Sun Z...Chen Q	36428756	2022

Sources

Genes for Leukemia, Acute Lymphoblastic 3

Genes related to Leukemia, Acute Lymphoblastic 3 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PAX5	Paired Box 5	Protein Coding	682.9	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Likely pathogenic ⁵ GeneCards inferred via : Disorders (show sections)	24013638

Sources

Variations for Leukemia, Acute Lymphoblastic 3

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic 3:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	PAX5	NM_016734.3(PAX5):c.547G>A (p.Gly183Ser)	SNV	Risk Factor	88892	rs398123063	GRCh37: 9:37002702-37002702 GRCh38: 9:37002705-37002705
2	PAX5	NM_016734.3(PAX5):c.253G>A (p.Gly85Arg)	SNV	Likely Pathogenic	1172745		GRCh37: 9:37015151-37015151 GRCh38: 9:37015154-37015154
3	PAX5	NM_016734.3(PAX5):c.419G>A (p.Arg140Gln)	SNV	Uncertain Significance	1210157		GRCh37: 9:37006526-37006526 GRCh38: 9:37006529-37006529
4	PAX5	NM_016734.3(PAX5):c.22C>T (p.Pro8Ser)	SNV	Uncertain Significance	1691541		GRCh37: 9:37034007-37034007 GRCh38: 9:37034010-37034010
5	PAX5	NM_016734.3(PAX5):c.1013-1G>A	SNV	Uncertain Significance	517139	rs1554646594	GRCh37: 9:36846927-36846927 GRCh38: 9:36846930-36846930
6	PAX5	NM_016734.3(PAX5):c.1169G>A (p.Arg390His)	SNV	Uncertain Significance	620603	rs771002648	GRCh37: 9:36840564-36840564 GRCh38: 9:36840567-36840567
7	PAX5	NM_016734.3(PAX5):c.701T>C (p.Leu234Pro)	SNV	Uncertain Significance	620623	rs753068558	GRCh37: 9:36966625-36966625 GRCh38: 9:36966628-36966628
8	PAX5	NM_016734.3(PAX5):c.1013-6A>G	SNV	Likely Benign	802486	rs1587737218	GRCh37: 9:36846932-36846932 GRCh38: 9:36846935-36846935
9	PAX5	NM_016734.3(PAX5):c.638C>T (p.Ser213Leu)	SNV	Likely Benign	135001	rs137870876	GRCh37: 9:36966688-36966688 GRCh38: 9:36966691-36966691